Abstract: Stroke is a serious neurological disease and the third leading cause of death in the western world. In roughly 15 % of the cases, the cause is due to an intracranial haemorrhage, and the remaining 85 % represent ischemic strokes. Ischemic stroke is caused by the occlusion of a cerebral artery either by an embolus or by local thrombosis. Several studies have shown an involvement of the endothelin system in ischemic stroke. This review aims to examine the alterations of vascular endothelin receptor expression in ischemic stroke. Furthermore, studies of the intracellular signalling pathways leading to the enhanced expression of vascular endothelin receptors show that both protein kinase C (PKC) and mitogen activating protein kinase (MAPK) play important roles. The results from this work provide new perspectives on the pathophysiology of ischemic stroke, and give a possible explanation to the beneficial effects of treatment with PKC and MAPK inhibitors to limit the infarct volume.
BACKGROUND
The ischemic injury that occurs after a stroke develops from a range of pathophysiological events. When the brain is deprived of oxygen and glucose, the membrane potentials of the neurons change rapidly, voltage-dependent Ca 2+ channels open and excitatory glutamate is released into the extracellular space [1] [2] [3] . The glutamate released results in increased levels of intracellular Na + , Cl -and Ca
2+
. The influx of Na + and Cl -is accompanied by osmotic water uptake which subsequently leads to oedema. The increased levels of intracellular Ca 2+ give rise to an activation of numerous enzyme systems, for example proteolytic enzymes that degrade the cytoskeleton, as well as phospholipase A2 and cyclooxygenase that generates free oxygen radicals. Beside their cell damaging characteristics, free oxygen radicals trigger inflammation and cell death in the ischemic area [4] [5] [6] [7] .
Between the ischemic core and the normal tissue lies the penumbra. This area has low blood flow and metabolism, but is not beyond salvaging [8, 9] . The penumbra is therefore a prime target for neuroprotective treatments. However, despite promising results from experimental animal models, several clinical studies have failed to show beneficial effects [10] [11] [12] .
VASCULAR PATHOPHYSIOLOGY
The vascular pathophysiology after an ischemic stroke can be divided into three phases [13] . In the first acute phase there are hemodynamic and metabolic changes that disrupt the blood-brain barrier. This is in part due to elevated levels of endothelin-1 (ET-1) [14, 15] . ET-1 along with other vasoactive factors, affects the myogenic tone, which is diminished in the acute phase [13, 16] . Reperfusion after an episode of cerebral ischemia results in the production of free oxygen radicals such as hydrogen peroxide and superoxide. The superoxide increases the blood-brain barrier permeability and disrupts the endothelial cell membranes [17, 18] .
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The following subacute phase takes place hours to days after the ischemic insult. In this there is gene activation of inflammatory mediators such as tumour necrosis factor-(TNF ) and interleukin-1 (IL-1 ), and transcription factors such as nuclear factor B [13, [19] [20] [21] . Furthermore, proteins with angiogenic and protective features like vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) are also expressed in this phase [22, 23] .
The chronic phase (days to months) after an episode of cerebral ischemia involves endothelial cell death due to inflammation as well as stimulation of angiogenic factors in the endothelial cells [13] .
ENDOTHELIN
In 1985, Hickey and colleagues discovered a novel vasoactive peptide, produced by the endothelial cells [24] . Three years later, Yanagisawa and colleagues isolated the peptide and named it endothelin (ET) [25] . Subsequent studies showed three different ET genes in the human genome, all coding for peptides of 21 amino acids; the original endothelin-1 (ET-1), endothelin-2 (ET-2) which differs with two amino acids, and endothelin-3 (ET-3) which differs with six amino acids compared to ET-1 [26] .
Translation of the ET-1 mRNA results in formation of preproendothelin, a peptide consisting of 212 amino acids [27] . Preproendothelin is converted into big ET-1, which exhibits some vasoactivity [28] . BigET-1 is cleaved by endothelin converting enzymes (ECE) to the mature endothelin peptide [29, 30] . ET-1 is produced primarily in endothelial cells, but can to some degree be found in other cell types, such as neurons, epithelial cells and macrophages [31] [32] [33] . The production and release of ET-1 is regulated by a range of different stimuli, such as thrombin, angiotensin, vasopressin and shear stress [34] [35] [36] . Interestingly, a group of cardiotoxic peptides found in the venom of the burrowing asp, the sarafotoxins, resemble the structure and function of ET-1 [37, 38] . They are able to activate the ET receptors, and sarafotoxin 6c (S6c) which we have used in the present investigations is a selective ET B receptor agonist [39] .
ENDOTHELIN RECEPTORS
There are two endothelin receptors in the vasculature of mammals, the endothelin A receptor (ET A ) and the endothelin B receptor (ET B ). Both are G-protein coupled receptors and both are found on the smooth muscle cells of the vasculature mediating contraction, albeit the ET A receptor in abundance [40] [41] [42] [43] [44] . However, an upregulation of ET B receptors has been seen in several cardiovascular diseases such as atherosclerosis [45, 46] , pulmonary hypertension [47] , ischemic heart disease [48] , cerebral ischemia [49, 50] as well as after organ culture [51] . In general the ET A and ET B receptors on the smooth muscle cells induce contraction by activation of phospholipase C (PLC) via G q proteins [52] . Activation of PLC hydrolyses phosphatidyl inositol (PIP 2 ) to inositol triphosphate (IP 3 ) and and 1,2-diacylglycerol (DAG). IP 3 causes Ca 2+ release from intracellular stores, giving rise to a transient smooth muscle contraction. In addition, DAG can activate protein kinase C (PKC) [53] . ET A also activates G s proteins, while ET B activates G i proteins [54] . These intracellular signalling events result in altered levels of cAMP, which affects the contractility of the smooth muscle cells [55] . ET A receptors also activate a Rho kinase pathway, suggested to produce the characteristic long-lasting contraction of ET-1 [52] .
Additionally, most part of the ET B receptors are found on the endothelial cells, mediating vasodilatation through the release of nitric oxide (NO) and prostacyclin [40, 56] . The ET A receptor has a similar affinity for ET-1 and ET-2 and lower affinity for ET-3, while the ET B receptor shows an equal affinity for all three ligands [57, 58] .
ENDOTHELIN AND ISCHEMIC STROKE
There are several studies pointing to a major role for the endothelin system in the pathophysiology of ischemic stroke [59] . For instance, it has been suggested that increased ETinduced contractility leads to decreased perfusion of the ischemic area and subsequently an enlargement of the ischemic core [60, 61] .
After an ischemic stroke the levels of ET-1 is increased in plasma, cerebrospinal fluid and cerebral tissue [62, 63] . In addition, exogenous ET-1 is able to decrease cerebral blood flow to levels that induce ischemia [64] . However, the responses to subtype specific ET receptor antagonists have proven to produce miscellaneous results. Selective ET A receptor antagonists increase cerebral perfusion and decrease the ischemic area in some studies [65, 66] but not in others [67, 68] . Similarly, the ET A /ET B receptor antagonist bosentan gives various results when used in models of ischemia [69] [70] [71] . Furthermore, an ET B receptor antagonist, BQ788, actually exacerbated the ischemic damage [72] . It is possible that this is due to the blockade of a local ET B receptor mediated vasodilatation in the cerebral ischemic region that is blocked by the antagonist. Thus, the use of ET receptor inhibitors might not be the best way to attenuate the ET system alterations after cerebral ischemia.
ENDOTHELIN RECEPTOR UPREGULATION AND ORGAN CULTURE
Based on the initial work (i) by Stenman [50] demonstrating that there is upregulation of ET B receptor after experimental cerebral ischemia in the MCA distributing to the ischemic region and (ii) the observation that organ culture of isolated ring segments of the MCA show similar upregulation [73] , we analysed the time-course of the ET receptor upregulation in cultured middle cerebral arteries [74] . To separate the ET A and ET B receptor mediated contractions, the ET B receptors were desensitized with S6c. The subsequent administration of ET-1 now only interacts with the ET A receptors [39] . In fresh arteries there is no ET B receptor mediated contraction, however, organ culture induces an upregulation of contractile ET B receptors, something that has been seen in many vessels [51, 75, 76] . There was a slight contractile response to S6c even at 6 hours of organ culture, and this response was increased by time in MCA incubated for 48 hours and the pEC 50 values were increased. The E max of the contractions induced by ET-1 did not change with organ culture (selective activation of ET A receptors). However, the pEC 50 of the dose-response curve of MCAs cultured for 48 hours was higher. This leftward shift has been described before, although that study was conducted on basilar arteries [75] . After 24 hours of organ culture, ET B mRNA levels are increased compared to fresh vessels, while the ET A mRNA levels remain unchanged [74] .
INTRACELLULAR SIGNAL TRANSDUCTION Protein Kinase C
To elucidate which intracellular mechanisms that are involved in the upregulation of ET B receptors we have examined the effects of a range of specific inhibitors; the transcriptional inhibitor actinomycin D and the translational inhibitor cycloheximide reduced the receptor upregulation [74] . This suggests that there is a production from gene level of new ET B receptors in organ culture, which is in accordance with previous studies performed in rat mesenteric arteries [77] .
The upregulation of ET B receptors has been found to be dependent on PKC in mesenteric arteries [78] and in the MCA [79] . The general PKC inhibitor, Ro-31-8220, attenuated both the contractile ET B receptor mediated response and the upregulated ET B receptor mRNA levels after organ culture. Ro-31-8220 inhibits not only PKC, but also other factors such as c-jun, JNK and mitogen-activated protein kinase phosphatase-1 (MKP-1) [80, 81] . Consequently, there is a risk that the inhibiting effect is not solely dependent on PKC. For that reason, four different PKC inhibitors were added to the medium in which MCA segments were cultured for 24 hours [79] . The functional responses showed that in MCA incubated with the PKC inhibitors bisindolylmaleimide I, Ro-32-0432 and PKC inhibitor 20-28 (a peptide mimicking an inactivating part of PKC) [82] the ET B receptor mediated contractions were diminished. The PKC inhibitors did not affect the ET A receptor mediated contractions [79] .
The real-time PCR showed that Ro-32-0432 decreased both the ET A and ET B receptor mRNA levels compared to control. Bisindolylmaleimide I decreased the ET B receptor mRNA levels, and showed tendency to decrease the ET A receptor mRNA levels, while PKC inhibitor 20-28 had no effect on the ET receptor mRNA. On the other hand, PKC inhibitor 20-28 was shown to be the most efficient inhibitor when measuring protein expression of ET B receptors in the MCA.
The discrepancy between the effects of the different PKC inhibitors on the mRNA level compared to the protein level can be explained in several ways. Ro-32-0432 and bisindolylmaleimide I might exert their inhibitory effects on PKC early in the production of new contractile ET B receptors, which causes the decrease in ET B receptor mRNA. In contrast, PKC inhibitor 20-28 might not come in play until the ET B receptor production reaches the protein levels. Bisindolylmaleimide I and Ro-32-0432 affected the ET B receptor protein levels as well, albeit marginally. However, this small decrease in receptor density in the arteries could be sufficient to diminish the functional response. Alternatively, the effect of PKC inhibitor 20-28 is more transient than for the two other inhibitors, and after 24 hours the ET B receptor mRNA might be restored to its original levels. Furthermore, these PKC inhibitors exhibit differences in the affinity for the PKC isoforms. Bisindolylmaleimide I inhibits the cPKCs ( , I, II, ) and PKC and PKC to a lesser extent [83, 84] . Ro-32-0432 primarily inhibits PKC , but in high concentrations Ro-32-0432 also inhibits the other isoforms of the cPKCs [85] . The PKC inhibitor 20-28 is based on a motif from the PKC and isoforms [82] . Western blot shows that PKC inhibitor 20-28 is able to decrease the protein amount of not only the PKC and isoforms, but of all five subtypes tested ( , I , , and ). The decrease was most prominent in the PKC and isoforms. Taken together, the differences in affinity could be important if there are several PKC isoforms that play a part in the ET B receptor upregulation after organ culture.
Mitogen Activating Protein Kinase (MAPK)
The MAPKs are important for a number of processes in different cell types and under a variety of conditions. The three major MAPKs are p38, ERK1/2 and SAPK/JNK pathways, each of them located at the end of a dynamic chain of kinases. Each MAPK is part of a signal pathway containing a MAPKKK that can activate MAPKKs, which in turn activate MAPKs (Fig. 1) . A kinase is able to phosphorylate several downstream targets. Accordingly, each cellular stimulus that results in MAPKKK activation can cascade through an increase in the number of active downstream kinases, which increases the signal strength at each step.
There are several different stimuli that are able to activate the p38 and SAPK/JNK pathways, whereas ERK1/2 activation differs somewhat. p38 and SAPK/JNK are considered inflammatory pathways and tend to be activated by inflammatory cytokines and cellular stress. ERK1/2 is considered more mitogenic and activated by growth factors [86] [87] [88] [89] . The MAPKs elicit some of their effects through the phosphorylation of transcription factors, thus initiating DNA binding and transcriptional regulation. The transcription factor activation is somewhat redundant between the various MAPKs, with the same transcription factor sometimes being activated by two or more MAPKs. There are also more direct effects of the MAPK activity in the form of cytokine mRNA transportation from the nucleus [90] , increased translation and stability of the mRNA [88, 91, 92] . MAPK activation is also able to affect cellular apoptosis [86] .
Thus, MAPK is activated by a range of extracellular stimuli, such as growth factors and cytokines. In a previous study we have shown that cytokines, which also activate the p38 MAPK, are able to increase the ET B receptor mediated contractions in arteries that has undergone organ culture [93] . Furthermore, PKC is known to activate the ERK1/2 MAPK pathway [94, 95] . Thus, the involvement of MAPK in the upregulation of ET B receptors after organ culture seemed plausible. Hence, we set out to investigate the involvement of ERK1/2 and p38 MAPK pathways in the upregulation of contractile ET B receptors after 24 hours of organ culture [96, 97] . The inhibitors selected for the ERK1/2 pathway were U0126, which inhibits MEK1/2, and SB386023, which inhibits raf (the MAPKKK of ERK1/2). To inhibit p38, SB239063 was added to the culture medium. The functional responses measured with myographs showed that in MCA incubated with the ERK1/2 pathway inhibitors, the ET B receptor upregulation was diminished. This was not obtained with the p38 inhibitor. Interestingly, the raf inhibitor SB386023 and the p38 inhibitor SB239063 enhanced the contractile responses to ET-1, pointing to a possible functional upregulation of ET A receptors [97] .
The real-time PCR partly confirmed our contractile experiments. U0126 and SB386023 diminished the ET B mRNA levels (although not significantly in the case of U0126) and SB386023 and SB239063 showed a tendency to elevate the ET A receptors mRNA levels. The difference between the functional ET A responses and the ET A mRNA levels could simply be due to the fact that the mRNA levels were increased at an earlier stage of the organ culture and at this time point is returning to their original values. The raf inhibitor SB386023 also modified the expression of the expression of ET B receptor protein on smooth muscle cells, which was established with immunohistochemistry [97] .
GENE EXPRESSION IN HUMAN BRAIN ARTERIES
While there is ample evidence of increased expression of vasoconstrictor receptors in cerebral arteries following experimental ischemia and after organ culture [50, [98] [99] [100] [101] [102] little is known of man [42, 100] . In studies designed to evaluate whether these receptors are upregulated in human cerebral arteries following ischemia as well we sampled human middle cerebral arteries after patients had died of cerebral ischemia [49] . The expression of ET A , ET B , AT 1 , AT 2 and 5-HT 2A/1B/1D receptors were investigated in human MCA following a thromboembolic stroke and compared with that in the MCA taken from subjects who were deceased due to extra cranial causes. There was upregulation of ET A , ET B and 5-HT 1B receptors as based on real-time PCR and of receptor protein expression of endothelin, 5-HT 1B and AT 1 receptors. The gene expression studies in the MCA leading to the ischemic region resulted in demonstration of 82 genes upregulated and 17 down regulated. The genes involved in cellular signaling, intra and extracellular-matrix-remodeling were regulated. Real-time PCR confirmed the changes in expression obtained by micro array [49] . Similar observations were seen in a micro array study of global cerebral ischemia in the rat [103] . The investigation based on micro array revealed changes in gene expression that supported the occurrence of dynamic changes in human cerebral arteries following thromboembolic stroke.
CEREBROVASCULAR SIGNAL TRANSDUCTION AFTER STROKE
Investigations of molecular changes in cerebral arteries after ischemia showed that there are similarities regarding upregulation of receptors following cerebral ischemia and after organ culture. In order to further investigate whether they share the activation of signal transduction pathways we have compared two models of cerebral ischemia and organ culture for cerebrovascular signal transduction [104] . The phosphorylation of different MAPKs (p38, ERK1/2 and SAPK/JNK) and their downstream transcription factors (ATF-2, Elk-1 and c-Jun) were investigated with immunohistochemistry using antibodies specific for the phosphorylated form of the MAPKs and the transcription factors. There was strong activation of the MAPKs following both cerebral ischemia and organ culture, whereas little or no activation was found in fresh arteries (Fig. 2) [104] . Comparable activation was seen of the downstream transcription factors (ATF-2, Elk-1 and c-Jun) as that of the MAPKs activation.
To verify the ability of the transcription factors to activate the transcription of these genes, the promoters of the genes were investigated. We found that there exists binding sites for the transcription factors in the promoters of the genes regulated, indicating that the MAPKs activated could be responsible for the transcriptional upregulation observed. We can thus conclude that there are similarities in the MAPK activation following cerebral ischemia and organ culture. This activation explains the observed gene upregulation and indicates that organ culture can be used as a tool to investigate molecular changes in cerebral arteries following ischemia.
ENDOTHELIN RECEPTORS AFTER CEREBRAL ISCHEMIA
Early studies in our group have shown that 48 hours after transient middle cerebral artery occlusion in rat, there is an upregulation of contractile ET B receptors in the ipsilateral MCA, similar to the one seen in organ culture, although not as prominent [50] . The further studies revealed that there is indeed an upregulation of contractile ET B receptors 24 hours after MCAO [96, 105] . The S6c induced response in the contralateral MCA was 8% of the potassium-induced reference contractions while it was 40% in the ischemic artery (Fig. 3) . There was a small upregulation of the ET A receptor mediated contractions which probably is true but only attains significance in some groups. This scenario is strengthened by the study in which contractile ET responses were analyzed 48 hours after the occlusion. In that study, there was a tendency towards upregulation of ET A receptors, however not significant [50] . These observations have been supported by protein expression studies with Western blot and immunocytochemistry.
SIGNAL TRANSDUCTION AND STROKE
As outline above, the inhibition of endothelin receptors does not give stable reductions in infarct volume. It is understandable since the micro array data suggested multiple gene activation. Following global ischemia there is upregulation of the 5-HT 1B [102] receptor and in focal ischemia of the angiotensin AT 1 receptor [98] . The natural question then appears if inhibition of the vascular signal transduction may modify the infarct volume in vivo. The effect of the PKC inhibitor Ro-32-0432 was verified by studied of the expression changes in the ET receptor after middle cerebral artery occlusion. Ro-32-0432 was given in conjunction with the occlusion, this inhibitor was able to diminish the upregulation of contractile ET B receptors [105] . This was accompanied by a decrease in brain damage and an improvement of neurological status of the animals.
Furthermore, we examined the effect of the ERK1/2 inhibitor U0126 in animals subjected to middle cerebral artery occlusion. U0126 was administered in conjunction with the occlusion [96] . This inhibitor was able to diminish the upregulation of contractile ET B receptors (Fig. 3) . It also decreased the brain damage and improved the neurological status of the animals.
CONCLUSIONS
The cerebral arteries participate actively in the response following an episode of cerebral ischemia in man and rat. The process involves activation of MAPK which in turn activate the transcription of inflammatory and extracellularmatrix-regulating genes as well as genes for specific vascular receptors. The signal transduction processes lead to powerful and prolonged effects of the initial activation. Because of the synergistic nature of these processes, involving several gene groups a single factor approach to the treatment of the sequels after cerebral ischemia seems unlikely to work since not only vasoconstrictor receptors are involved but also genes for inflammation and apoptosis. Modulating of the MAPK activation and selectively affecting the expression of inflammatory and extracellular-matrix-related genes could thus allow for a novel approach to the treatment of cerebral ischemia.
